Continuing with the abstract series covering the topics at the Eagle Symposium 2015, the following was kindly provided by David Williams, CEO at Discuva, who will be addressing the subject of "Discovering New Antibiotics: A Straightforward Process"
Abstract: "The use of new discovery techniques and treatment paradigms will be discussed to demonstrate there are practical solutions to the problem of antimicrobial resistance. These principles are applicable for therapeutics across all disease areas. The solutions discussed will require changes in our current thinking on drug design."
Speaker's Bio: David co-founded the Next Generation Antibiotics company Discuva, based in Cambridge UK, which uses innovative proprietary technologies to discover novel small molecule antibacterial agents and the spin-off sister company Bactevo (New Medicines from Accelerated Microbial Evolution). David has 30 years’ experience in large Pharma and Biotech, with active involvement in all stages of research from target discovery and translational research through to Phase II clinical studies. In addition, he has successfully forged commercial deals with many major Pharma including Genentech, Roche, Novartis, Bayer and AstraZeneca and authored or co-authored over 60 publications and patents. David co-founded the successful AIM-listed oncology drug discovery company Sareum and as part of the senior management steered Summit plc back to financial and scientific viability. Other major roles in UK/US senior management and research were performed at Millennium Pharmaceuticals, Medivir, Acambis and Roche.
Eagle Symposium 2015: Eagle Genomics organises an annual industry symposium in the promotion of innovation and advancement in genomics, bioinformatics, and computational biology to help address global issues. The Eagle Symposium 2015 builds on the theme "Bridging Biology and Informatics for R&D Innovation", taking place on 23 March 2015 at the European Bioinformatics Institute (EBI), Wellcome Trust Genome Campus in Hinxton, Cambridge, UK.